...
search icon
ibrx-img

Immunitybio Inc Share Price

IBRX
NSQ
$6.892
+$0.27
(4.08%)
1D
Industry: Biotechnology Sector: Health Care

Immunitybio Inc Analyst Forecast

Immunitybio Inc Share Price Chart

Immunitybio Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$6.52B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
918.73K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.02
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.83 L
$8.28 H
$6.892

About Immunitybio Inc, Common Stock

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California. more

Industry: BiotechnologySector: Health Care

Immunitybio Inc Stock Returns

Time FrameIBRXSectorS&P500
1-Week Return17.38%0.75%0.54%
1-Month Return155.6%-0.88%-2.01%
3-Month Return221.36%2.08%-0.28%
6-Month Return168.02%18.91%6.04%
1-Year Return104.32%6.98%12.92%
3-Year Return75.6%16.78%65.15%
5-Year Return-78.59%33.02%73.52%
10-Year Return1.85%142.35%266.07%

Immunitybio Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue605.00K934.00K240.00K622.00K14.74M[{"date":"2020-12-31","value":4.1,"profit":true},{"date":"2021-12-31","value":6.33,"profit":true},{"date":"2022-12-31","value":1.63,"profit":true},{"date":"2023-12-31","value":4.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue9.15M-24.19M18.51M17.55M[{"date":"2020-12-31","value":37.81,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.52,"profit":true},{"date":"2024-12-31","value":72.56,"profit":true}]
Gross Profit605.00K934.00K240.00K622.00K14.74M[{"date":"2020-12-31","value":4.1,"profit":true},{"date":"2021-12-31","value":6.33,"profit":true},{"date":"2022-12-31","value":1.63,"profit":true},{"date":"2023-12-31","value":4.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses221.49M331.21M351.54M362.87M358.93M[{"date":"2020-12-31","value":61.04,"profit":true},{"date":"2021-12-31","value":91.28,"profit":true},{"date":"2022-12-31","value":96.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":98.91,"profit":true}]
Operating Income(220.88M)(330.28M)(351.30M)(362.25M)(344.18M)[{"date":"2020-12-31","value":-22088000000,"profit":false},{"date":"2021-12-31","value":-33028000000,"profit":false},{"date":"2022-12-31","value":-35129800000,"profit":false},{"date":"2023-12-31","value":-36225000000,"profit":false},{"date":"2024-12-31","value":-34418200000,"profit":false}]
Total Non-Operating Income/Expense(12.50M)(33.57M)(126.80M)(345.27M)(221.39M)[{"date":"2020-12-31","value":-1250200000,"profit":false},{"date":"2021-12-31","value":-3357200000,"profit":false},{"date":"2022-12-31","value":-12679500000,"profit":false},{"date":"2023-12-31","value":-34527500000,"profit":false},{"date":"2024-12-31","value":-22139000000,"profit":false}]
Pre-Tax Income(226.03M)(349.84M)(417.29M)(583.89M)(413.64M)[{"date":"2020-12-31","value":-22603300000,"profit":false},{"date":"2021-12-31","value":-34983900000,"profit":false},{"date":"2022-12-31","value":-41728600000,"profit":false},{"date":"2023-12-31","value":-58389200000,"profit":false},{"date":"2024-12-31","value":-41364500000,"profit":false}]
Income Taxes(1.85M)9.00K34.00K(40.00K)81.00K[{"date":"2020-12-31","value":-2279.01,"profit":false},{"date":"2021-12-31","value":11.11,"profit":true},{"date":"2022-12-31","value":41.98,"profit":true},{"date":"2023-12-31","value":-49.38,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(224.19M)(349.85M)(417.32M)(583.85M)(413.73M)[{"date":"2020-12-31","value":-22418700000,"profit":false},{"date":"2021-12-31","value":-34984800000,"profit":false},{"date":"2022-12-31","value":-41732000000,"profit":false},{"date":"2023-12-31","value":-58385200000,"profit":false},{"date":"2024-12-31","value":-41372600000,"profit":false}]
Income From Continuous Operations(92.38M)(349.85M)(417.32M)(458.76M)(413.64M)[{"date":"2020-12-31","value":-9238300000,"profit":false},{"date":"2021-12-31","value":-34984800000,"profit":false},{"date":"2022-12-31","value":-41732000000,"profit":false},{"date":"2023-12-31","value":-45876400000,"profit":false},{"date":"2024-12-31","value":-41364500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(221.85M)(346.79M)(416.57M)(583.20M)(413.56M)[{"date":"2020-12-31","value":-22185100000,"profit":false},{"date":"2021-12-31","value":-34679000000,"profit":false},{"date":"2022-12-31","value":-41656700000,"profit":false},{"date":"2023-12-31","value":-58319600000,"profit":false},{"date":"2024-12-31","value":-41356400000,"profit":false}]
EPS (Diluted)(0.89)(0.89)(1.05)(1.13)(0.60)[{"date":"2020-12-31","value":-89,"profit":false},{"date":"2021-12-31","value":-89,"profit":false},{"date":"2022-12-31","value":-105,"profit":false},{"date":"2023-12-31","value":-113,"profit":false},{"date":"2024-12-31","value":-60.32,"profit":false}]

Immunitybio Inc Ratios

Immunitybio Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

IBRX
Cash Ratio 2.69
Current Ratio 5.77
Quick Ratio 5.65

Immunitybio Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IBRX
ROA (LTM) -36.89%
ROE (LTM) 0.00%

Immunitybio Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IBRX
Debt Ratio Lower is generally better. Negative is bad. 1.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.10

Immunitybio Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IBRX
Trailing PE NM
Forward PE NM
P/S (TTM) 78.03
P/B 0.00
Price/FCF NM
EV/R 81.30
EV/Ebitda NM

FAQs

What is Immunitybio Inc share price today?

Immunitybio Inc (IBRX) share price today is $6.892

Can Indians buy Immunitybio Inc shares?

Yes, Indians can buy shares of Immunitybio Inc (IBRX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IBRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immunitybio Inc be purchased?

Yes, you can purchase fractional shares of Immunitybio Inc (IBRX) via the Vested app. You can start investing in Immunitybio Inc (IBRX) with a minimum investment of $1.

How to invest in Immunitybio Inc shares from India?

You can invest in shares of Immunitybio Inc (IBRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in IBRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immunitybio Inc shares
What is Immunitybio Inc 52-week high and low stock price?

The 52-week high price of Immunitybio Inc (IBRX) is $8.28. The 52-week low price of Immunitybio Inc (IBRX) is $1.83.

What is Immunitybio Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Immunitybio Inc (IBRX) is

What is Immunitybio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immunitybio Inc (IBRX) is 0.00

What is Immunitybio Inc dividend yield?

The dividend yield of Immunitybio Inc (IBRX) is 0.00%

What is the Market Cap of Immunitybio Inc?

The market capitalization of Immunitybio Inc (IBRX) is $6.52B

What is Immunitybio Inc's stock symbol?

The stock symbol (or ticker) of Immunitybio Inc is IBRX

How Can Investors Use Immunitybio Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Immunitybio Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Immunitybio Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Immunitybio Inc shares for Indian investors?

When investing in Immunitybio Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Immunitybio Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Immunitybio Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Immunitybio Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Immunitybio Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top